John A Chukinas
Overview
Explore the profile of John A Chukinas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
69
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Popescu B, Stahlhut C, Tarver T, Wishner S, Lee B, Peretz C, et al.
Cell Rep Med
. 2023 Nov;
4(11):101290.
PMID: 37992684
Mutations in the receptor tyrosine kinases (RTKs) FLT3 and KIT are frequent and associated with poor outcomes in acute myeloid leukemia (AML). Although selective FLT3 inhibitors (FLT3i) are clinically effective,...
2.
Glisovic-Aplenc T, Diorio C, Chukinas J, Veliz K, Shestova O, Shen F, et al.
Blood Adv
. 2023 May;
7(16):4418-4430.
PMID: 37171449
Many hematologic malignancies are not curable with chemotherapy and require novel therapeutic approaches. Chimeric antigen receptor (CAR) T-cell therapy is 1 such approach that involves the transfer of T cells...
3.
Niswander L, Graff Z, Chien C, Chukinas J, Meadows C, Leach L, et al.
Haematologica
. 2022 Aug;
108(2):457-471.
PMID: 35950535
Chimeric antigen receptor (CAR) T-cell immunotherapies targeting CD19 or CD22 induce remissions in the majority of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), although relapse due to target antigen...
4.
Qin H, Yang L, Chukinas J, Shah N, Tarun S, Pouzolles M, et al.
J Immunother Cancer
. 2021 Sep;
9(9).
PMID: 34531250
Background: Successful development of chimeric antigen receptor (CAR) T cell immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia (AML) is highly desired given their poor clinical prognosis and...